---
title: "Elicio Therapeutics Falls 13% After Hours as Pancreatic Cancer Drug Data Draws Focus"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290105601.md"
description: "ELTX drops 13% in after-hours trading to $4.08 after surging over 70% during regular session on positive pancreatic cancer trial data."
datetime: "2026-06-17T21:00:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290105601.md)
  - [en](https://longbridge.com/en/news/290105601.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290105601.md)
generator: "portal-rs"
---

# Elicio Therapeutics Falls 13% After Hours as Pancreatic Cancer Drug Data Draws Focus

Elicio Therapeutics(ELTX.US) 盘后跌超 13%，现报 4.08 美元。

该股在常规交易时段大涨超 70%，此前公司公布 ELI-002 7P 联合 Opdivo 在 KRAS 突变胰腺癌患者中显示出持久完全缓解数据。

公司计划推进 Phase 1 联合试验，结合化疗与抗 PD-1 抑制剂治疗转移性 mKRAS 胰腺癌。

### Related Stocks

- [ELTX.US](https://longbridge.com/en/quote/ELTX.US.md)

## Related News & Research

- [Elicio opens Phase 1 neoadjuvant ELI-002 7P trial in resectable pancreatic cancer at MSK](https://longbridge.com/en/news/295403408.md)
- [Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering | ELTX Stock News](https://longbridge.com/en/news/291495074.md)
- [Elicio Therapeutics posts AMPLIFY-7P presentation on ELI-002 7P in metastatic mKRAS pancreatic cancer](https://longbridge.com/en/news/290828766.md)
- [Elicio Therapeutics Pancreatic Cancer Study Disappoints](https://longbridge.com/en/news/289811449.md)
- [Elicio Therapeutics Points To Durable Responses As It Maps Next Steps For Lead Cancer Drug](https://longbridge.com/en/news/290083011.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**